The CREBBP (CREB-binding protein) antibody is a crucial tool in studying the functional roles of the CREBBP protein, a transcriptional coactivator involved in regulating gene expression through histone acetylation. CREBBP, located on chromosome 16p13.3. interacts with CREB (cAMP response element-binding protein) and other transcription factors to modulate chromatin structure and enhance transcriptional activation. It contains a histone acetyltransferase (HAT) domain, enabling it to acetylate histones and non-histone proteins, thereby influencing cellular processes like cell growth, differentiation, and DNA repair. Dysregulation of CREBBP is linked to cancers (e.g., lymphomas, acute leukemia) and Rubinstein-Taybi syndrome, a developmental disorder caused by CREBBP mutations.
CREBBP antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and chromatin immunoprecipitation (ChIP) to detect protein expression, localization, and DNA-binding interactions. These antibodies help elucidate CREBBP's role in signaling pathways (e.g., Wnt, p53) and its partnership with paralog EP300. Researchers also employ CREBBP antibodies to explore its involvement in epigenetic regulation, immune responses, and therapeutic targeting in diseases. Validating antibody specificity is critical, as CREBBP shares functional domains with EP300. Overall, CREBBP antibodies are indispensable for unraveling its contributions to both normal physiology and pathology.